

KAN RESEARCH INSTITUTE COMMENCES FULL-SCALE OPERATION AT NEW FACILITY

VER1079(1810)-24()7]TJ 0 Tc4. EW [4ET1079(1810)-24()7]TJ 4ET1079c-
INTERNATIONAL STRATEGIC INNOVATION ZONE

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced that its research and development subsidiary KAN Research Institute, Inc. (Headquarters: Hyogo Prefecture, President & CEO: Toshio Imai, "KRI") held a dedication ceremony today for its new research facility in Kobe, Hyogo prefecture, and has now officially commenced full-scale operation of its research and development activities at this facility.

Second from left to right: Toshiro Tamada, Vice Mayor, City of Kobe, Toshio Imai, President & CEO, KAN Research Institute, Inc., Haruo Naito, President & CEO, Eisai Co., Ltd., Hideki Hayashi, Deputy President (Representative Corporate Officer), Eisai Co., Ltd.

KRI is a research group that aims to discover and develop new drugs based on novel therapeutic concepts as a unit of Eisai Product Creation Systems. Specifically, KRI is dedicated to conducting discovery research based on the concept of "Integrative Cell Biology for Medicine"

opportunity to relocate to a new research facility within the Zone in order to strengthen its research capabilities and increase the scale of its research.

The new research facility, located within the Kobe Biomedical Innovation Cluster, has a total floor space approximately 12,000m

², or roughly five times that of its previous premises, with the capacity to house around 100 researchers, more than twice the present number. With the laboratory specifications allowing

2. About KAN Research Institute, Inc.

KAN Research Institute, Inc. is a 100% wholly owned research and development subsidiary of Eisai Co., Ltd. It is a research group that aims to discover and develop new drugs based on novel therapeutic concepts within Eisai's research and development system called Eisai Product Creation Systems. Initially established with its strengths in